Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism

Molecular Metabolism

Volumn 3, Issue 1, 2014, Pages 19-28

  Marcelin, Geneviève ^a   Jo, Young Hwan ^a   Li, Xiaosong ^a   Schwartz, Gary J ^a   Zhang, Ying ^b,d   Dun, Nae J ^b   Lyu, Rong Ming ^c   Blouet, Clémence ^a   Chang, Jaw K ^c   Chua Jr , Streamson ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PHOENIX PHARMACEUTICALS INC   (United States)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

AGRP NPY neurons; Diabetes; FGF19; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HYPOTHALAMUS; INSULIN RESISTANCE; LEPTIN DEFICIENCY; LIPID DIET; MOUSE; MOUSE MODEL; NERVE FUNCTION; NEUROMODULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 84893411706     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.10.002     Document Type: Article

References (42)

1. Song K.H., Li T., Owsley E., Strom S., Chiang J.Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
2. Holt J.A., Luo G., Billin A.N., Bisi J., McNeill Y.Y., Kozarsky K.F., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes and Development 2003, 17:1581-1591.
3. Chiang J.Y. Bile acids: regulation of synthesis. Journal of Lipid Research 2009, 50:1955-1966.
4. Kir S., Beddow S.A., Samuel V.T., Miller P., Previs S.F., Suino-Powell K., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331:1621-1624.
5. Potthoff M.J., Boney-Montoya J., Choi M., He T., Sunny N.E., Satapati S., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metabolism 2011, 13:729-738.
6. Tomlinson E., Fu L., John L., Hultgren B., Huang X., Renz M., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
7. de Wit N.J., Bosch-Vermeulen H., de Groot P.J., Hooiveld G.J., Bromhaar M.M., Jansen J., et al. The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. Biomed Central Medical Genomics 2008, 1:14.
8. Stejskal D., Karpisek M., Hanulova Z., Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scandinavian Journal of Clinical and Laboratory Investigation 2008, 68:501-507.
9. Angelin B., Larsson T.E., Rudling M. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metabolism 2012, 16:693-705.
10. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
11. Fu T., Choi S.E., Kim D.H., Seok S., Suino-Powell K.M., Xu H.E., et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proceedings of the National Academy of Sciences 2012, 109:16137-16142.
12. Schreuder T.C., Marsman H.A., Lenicek M., van Werven J.R., Nederveen A.J., Jansen P.L., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology - Gastrointestinal and Liver Physiology 2010, 298:G440-445.
13. Yu C., Wang F., Kan M., Jin C., Jones R.B., Weinstein M., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. Journal of Biological Chemistry 2000, 275:15482-15489.
14. Ge H., Baribault H., Vonderfecht S., Lemon B., Weiszmann J., Gardner J., et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One 2012, 7:e33603.
15. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. Journal of Biological Chemistry 2007, 282:26687-26695.
16. Kharitonenkov A., Dunbar J.D., Bina H.A., Bright S., Moyers J.S., Zhang C., et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Journal of Cellular Physiology 2008, 215:1-7.
17. Wu A.L., Coulter S., Liddle C., Wong A., Eastham-Anderson J., French D.M., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011, 6:e17868.
18. Wu X., Ge H., Lemon B., Weiszmann J., Gupte J., Hawkins N., et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proceedings of the National Academy of Sciences 2009, 106:14379-14384.
19. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 2009, 8:235-253.
20. Yang C., Jin C., Li X., Wang F., McKeehan W.L., Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 2012, 7:e33870.
21. Ryan K.K., Kohli R., Gutierrez-Aguilar R., Gaitonde S.G., Woods S.C., Seeley R.J. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013, 154:9-15.
22. Sun H.D., Malabunga M., Tonra J.R., DiRenzo R., Carrick F.E., Zheng H., et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. American Journal of Physiology - Endocrinology and Metabolism 2007, 292:E964-976.
23. Wu A.L., Kolumam G., Stawicki S., Chen Y., Li J., Zavala-Solorio J., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Science Translational Medicine 2011, 3:113ra126.
24. Hagan M.M. Peptide YY: a key mediator of orexigenic behavior. Peptides 2002, 23:377-382.
25. Dun S.L., Brailoiu G.C., Tica A.A., Yang J., Chang J.K., Brailoiu E., et al. Neuronostatin is co-expressed with somatostatin and mobilizes calcium in cultured rat hypothalamic neurons. Neuroscience 2010, 166:455-463.
26. Marcelin G., Liu S.M., Schwartz G.J., Chua S. Identification of a loss-of-function mutation in Ube2l6 associated with obesity resistance. Diabetes 2012, 62(8):2784-2795.
27. Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., Schwartz M.W. Central nervous system control of food intake and body weight. Nature 2006, 443:289-295.
28. Morton G.J., Schwartz M.W. Leptin and the central nervous system control of glucose metabolism. Physiological Reviews 2011, 91:389-411.
29. Hoffman G.E., Smith M.S., Verbalis J.G. c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems. Frontiers in Neuroendocrinology 1993, 14:173-213.
30. Munzberg H., Jobst E.E., Bates S.H., Jones J., Villanueva E., Leshan R., et al. Appropriate inhibition of orexigenic hypothalamic arcuate nucleus neurons independently of leptin receptor/STAT3 signaling. Journal of Neuroscience 2007, 27:69-74.
31. Olofsson L.E., Pierce A.A., Xu A.W. Functional requirement of AgRP and NPY neurons in ovarian cycle-dependent regulation of food intake. Proceedings of the National Academy of Sciences 2009, 106:15932-15937.
32. Obici S., Feng Z., Tan J., Liu L., Karkanias G., Rossetti L. Central melanocortin receptors regulate insulin action. Journal of Clinical Investigation 2001, 108:1079-1085.
33. Klebig M.L., Wilkinson J.E., Geisler J.G., Woychik R.P. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proceedings of the National Academy of Sciences 1995, 92:4728-4732.
34. Lu D., Willard D., Patel I.R., Kadwell S., Overton L., Kost T., et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994, 371:799-802.
35. Ciofi P. The arcuate nucleus as a circumventricular organ in the mouse. Neuroscience Letters 2010, 487:187-190.
36. Warne J.P., Xu A.W. Metabolic transceivers: in tune with the central melanocortin system. Trends in Endocrinology and Metabolism 2013, 24(2):68-75.
37. Morton, G.J., Matsen, M.E., Bracy, D.P., Meek, T.H., Nguyen, H.T., Stefanovski, D., et al. FGF19 action in the brain induces insulin-independent glucose lowering. Journal of Clinical Investigation, http://dx.doi.org/10.1172/JCI70710.
38. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. American Journal of Physiology - Endocrinology and Metabolism 2008, 294:E15-26.
39. Polyzogopoulou E.V., Kalfarentzos F., Vagenakis A.G., Alexandrides T.K. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003, 52:1098-1103.
40. Pournaras D.J., Osborne A., Hawkins S.C., Vincent R.P., Mahon D., Ewings P., et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Annals of Surgery 2010, 252:966-971.
41. Pournaras D.J., Glicksman C., Vincent R.P., Kuganolipava S., Alaghband-Zadeh J., Mahon D., et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012, 153:3613-3619.
42. Wu Q., Whiddon B.B., Palmiter R.D. Ablation of neurons expressing agouti-related protein, but not melanin concentrating hormone, in leptin-deficient mice restores metabolic functions and fertility. Proceedings of the National Academy of Sciences 2012, 109:3155-3160.